NOT KNOWN FACTS ABOUT SUVOREXANT

Avoid concomitant usage of tucatinib with CYP3A substrates, where nominal concentration improvements might bring on serious or lifestyle-threatening toxicities. If unavoidable, minimize CYP3A substrate dose In line with product or service labeling.Stay clear of concomitant utilization of tucatinib with CYP3A substrates, exactly where minimal focus